đź’ŠArdelyx Faces Regulatory Setback, Arcturus Advances in Phase 2, Abbvie Under Pressure | Biotech Sector Insights

REGN, GILD, AMGN, INCY, and BIIB all showing negative returns. Of note is a class-action lawsuit against Biogen Inc., impacting financials and reputation; investors may seek recovery through Levi & Korsinsky until July 22, 2024.

Welcome to the MarketReader Minute.

Below are AI-generated insights on moves in the health care/biotechnology sector, powered by MarketReader technology.

Tuesday, July 2

IBB [+0.4%]
The iShares Biotechnology ETF experienced significant movements in its holdings, with top contributors like REGN, GILD, AMGN, INCY, and BIIB all showing negative returns. Of note is a class-action lawsuit against Biogen Inc., impacting financials and reputation; investors may seek recovery through Levi & Korsinsky until July 22, 2024.

Read more